You are here: Home
Mylan and Gilead partner for TAF-based HIV treatments in developing markets

Mylan and Gilead partner for TAF-based HIV treatments in developing markets

Mylan Laboratories has signed an agreement with Gilead Sciences to increase access to Tenofovir Alafenamide (TAF) based HIV treatments in developing countries....

AstraZeneca (AZ) and Eli Lilly have started AMARANTH, a phase II/III study investigating a potential treatment for early Alzheimer's disease.

AstraZeneca (AZ) and Eli Lilly have started AMARANTH, a phase II/III study investigating a potential treatment for early Alzheimer's disease.

The trial will examine oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293, also known as LY3314814, which reduced levels of amyloid-beta in the cereb...

EFPIA hails joint action on counterfeit drugs

EFPIA hails joint action on counterfeit drugs

The pan-European medicines verification system uses an anti-tampering device together with 2D barcoding to verify the authenticity of medicinal products and is...

Banner

Knowledge Bank

Edit

Amount of short articles:

Amount of articles links:

You can order sections with dragging on list bellow:

  • Knowledge Bank
  • Business & Industry
Save
Cancel
Reset

News

Mylan and Gilead partner for TAF-based HIV treatments in developing

Mylan Laboratories has signed an agreement with Gilead Sciences to increase access to Tenofovir Alafenamide (TAF) based HIV treatments in developing

Tuesday, 9 December 2014 Comments

Press Releases

TxCell receives EU Orphan Drug Designation for Col-Treg in the treatment of non-infectious

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today

Thursday, 18 December 2014 Comments

Research Insight

UK Medical Research Council scientists create world's first synthetic

Scientists at the UK's Medical Research Council (MRC) have created the world's first enzymes made from artificial genetic material, which are capable of triggering chemical reactions in the

Tuesday, 2 December 2014 Comments

Techno Trends

Insourcing IV Sterile

Determined to cement access to reliable and safe sources for crucial IV drug admixtures, a growing number of hospitals are bringing production of compounded sterile products (CSPs) in-house and turning

Wednesday, 25 June 2014 Comments

Industry Reports

Pfizer acquires Baxter's marketed vaccines portfolio for

US-based drug maker Pfizer has completed the acquisition of marketed vaccines portfolio from Baxter International for

Tuesday, 2 December 2014 Comments

Articles

Why streamlining pharma supply chain is

For most pharmaceuticals executives, the prospect of the patent cliff is looming large in their thoughts. But an additional – and less obvious – challenge is also ready to derail

Wednesday, 18 July 2012 Comments

Business & Industry

Edit

Amount of short articles:

Amount of articles links:

You can order sections with dragging on list bellow:

  • Knowledge Bank
  • Business & Industry
Save
Cancel
Reset

Drug Research

Sanofi, Fraunhofer create new natural product center of

French pharmaceutical firm Sanofi and Germany-based Fraunhofer-Gesellschaft have formed a natural product center of excellence to speed up the discovery and development of new therapies to treat infectious

Friday, 17 January 2014 Comments

Production & Manufacturing

Galena Biopharma Acquires Mills

Galena Biopharma, a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced it has acquired Mills Pharmaceuticals, which has

Thursday, 16 January 2014 Comments

Packaging & Labelling

Canada unveils new labeling initiative to enhance drug

Canada has rolled out the plain language labeling initiative to improve the safe use of medicines by making drug labels and safety information easier to read and understand for all

Monday, 17 June 2013 Comments

Strategy

OncoMed Pharmaceuticals and Bayer HealthCare Expand Cancer Stem Cell Collaboration with Clinical Manufacturing

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics targeting cancer stem cells, today announced it has expanded its collaboration with Bayer HealthCare. Bayer’s U.S. affiliate will manufacture clinical supplies of

Saturday, 21 July 2012 Comments

Clinical Trials

TxCell announces start of phase IIb clinical trial with Ovasave(R) for refractory Crohn’s

TxCell undertaking one of largest ever controlled studies for a personalized T cell immunotherapy product . Top line results of this study are expected end 2016/early 2017.TxCell SA (FR0010127662 –

Friday, 5 December 2014 Comments

IT & Data Management

Pharma Security Group introduces new medication reminder

Pharma Security Group (PSG) has introduced a new medication reminder service, myPharmaCall, designed for users to set up daily phone call reminders for their

Thursday, 22 August 2013 Comments

Banner